<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00074243</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000343702</org_study_id>
    <secondary_id>NCI-04-C-0035</secondary_id>
    <nct_id>NCT00074243</nct_id>
    <nct_alias>NCT00071864</nct_alias>
  </id_info>
  <brief_title>CC-8490 in Treating Patients With Recurrent or Refractory High-Grade Gliomas</brief_title>
  <official_title>A Phase I Trial Of CC-8490 For The Treatment Of Patients With Recurrent/Refractory High-Grade Gliomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as CC-8490, work in different ways to stop tumor&#xD;
      cells from dividing so they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of CC-8490 in treating patients who have&#xD;
      recurrent or refractory high-grade gliomas.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose of CC-8490 in patients with recurrent or refractory&#xD;
           high-grade gliomas.&#xD;
&#xD;
        -  Determine, preliminarily, the toxic effects of this drug in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this drug in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine, preliminarily, the potential anti-glioma activity of this drug in these&#xD;
           patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive oral CC-8490 once daily on days 1 and 3-28 (course 1 only). Beginning with&#xD;
      course 2 and for all subsequent courses, patients receive oral CC-8490 once daily on days&#xD;
      1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of CC-8490 until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6&#xD;
      patients experience dose-limiting toxicity. Once the MTD is determined, a total of 10&#xD;
      patients are treated at that dose.&#xD;
&#xD;
      Patients are followed within 2 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 34 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2003</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-8490</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed supratentorial malignant glioma, including any of the&#xD;
             following:&#xD;
&#xD;
               -  Glioblastoma multiforme&#xD;
&#xD;
               -  Gliosarcoma&#xD;
&#xD;
               -  Anaplastic astrocytoma&#xD;
&#xD;
               -  Anaplastic oligodendroglioma&#xD;
&#xD;
               -  Anaplastic mixed oligoastrocytoma&#xD;
&#xD;
               -  Malignant glioma/astrocytoma not otherwise specified OR&#xD;
&#xD;
          -  Clinical and radiographic diagnosis of progressive low-grade glioma&#xD;
&#xD;
          -  Radiographically diagnosed infiltrating brain stem gliomas not amenable to biopsy&#xD;
             allowed&#xD;
&#xD;
          -  Recurrent or progressive disease as determined by 1 of the following:&#xD;
&#xD;
               -  CT scan or MRI within the past 21 days&#xD;
&#xD;
               -  Biopsy within the past 12 weeks&#xD;
&#xD;
          -  Failed prior radiotherapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 8 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Granulocyte count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3 (transfusion independent)&#xD;
&#xD;
          -  Hemoglobin at least 8 g/dL (transfusion allowed)&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  AST and ALT no greater than 2 times upper limit of normal&#xD;
&#xD;
          -  No significant active hepatic disease that would preclude study participation&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
          -  No significant active renal disease that would preclude study participation&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No significant active cardiac disease that would preclude study participation&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 2 months after study&#xD;
             participation&#xD;
&#xD;
          -  No other malignancy within the past 3 years except nonmelanoma skin cancer or&#xD;
             carcinoma in situ of the cervix&#xD;
&#xD;
          -  No significant active psychiatric disease that would preclude study participation&#xD;
&#xD;
          -  No other condition or laboratory abnormality that would preclude study participation&#xD;
&#xD;
          -  Able to swallow capsules whole&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  At least 2 weeks since prior interferon&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  At least 2 weeks since prior vincristine&#xD;
&#xD;
          -  At least 3 weeks since prior procarbazine&#xD;
&#xD;
          -  At least 4 weeks since prior temozolomide or carboplatin&#xD;
&#xD;
          -  At least 6 weeks since prior nitrosoureas&#xD;
&#xD;
          -  No other concurrent anticancer chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  At least 2 weeks since prior tamoxifen&#xD;
&#xD;
          -  Concurrent steroids allowed provided dose has been stable for at least 5 days prior to&#xD;
             study enrollment&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 2 weeks since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  At least 2 weeks since prior resection of a recurrent or progressive tumor&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 2 weeks since other prior non-cytotoxic therapy&#xD;
&#xD;
          -  At least 4 weeks since other prior cytotoxic therapies&#xD;
&#xD;
          -  More than 28 days since prior experimental study drugs&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Howard A. Fine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NCI - Neuro-Oncology Branch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2006</verification_date>
  <study_first_submitted>December 10, 2003</study_first_submitted>
  <study_first_submitted_qc>December 10, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2003</study_first_posted>
  <last_update_submitted>April 29, 2015</last_update_submitted>
  <last_update_submitted_qc>April 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2015</last_update_posted>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult anaplastic oligodendroglioma</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult mixed glioma</keyword>
  <keyword>adult brain stem glioma</keyword>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

